Sofosbuvir/Ribavirin treatment in patients with genotype 2, Hepatitis C Virus infection and symptomatic mixed cryoglobulinemia: an interim analysis on safety, efficacy and impact on quality of life

Cerretelli, Guia; Gragnani, Laura; Monti, Monica; Arena, Umberto; Fognani, Elisa; Petraccia, Luisa; Gianni, Elena; Sollima, S.; Brancaccio, Giuseppina; Galli, Massimo; Gaeta, G.B.; Zignego, A.L.

doi:10.1016/s0168-8278(17)31410-1

Cited by 9 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several centers have published their experience with novel DAA therapies in HCV‐MCS, including agents such as sofosbuvir, simeprevir, daclatasvir, ledipasvir, asunaprevir, dasabuvir, pariteprevir, and ombitasvir (Table ). Studies demonstrate that DAA regimens achieve SVR in 95% (297 out of 313) of patients with HCV‐MCS, which is similar to cure rates in the general population with HCV . There are currently no reports of HCV‐MCS treated with more recently approved DAAs, such as sofosbuvir/velpatasvir/voxilaprevir, elbasvir/grazoprevir, glecaprevir/pibrentasvir, or sofosbuvir/velpatasvir, but there is no reason to think that these agents would be less effective in HCV‐MCS.…”

Section: Direct‐acting Antiviral Treatment In Mixed Cryoglobulinemia mentioning

confidence: 95%

“…The most common SAE reported was anemia in the setting of RBV use with DAA, and when RBV‐containing DAA studies are excluded, there were no SAEs reported in 77 patients. Overall, only 3/192 (1.6%) patients treated with IFN‐free DAAs discontinued treatment early …”

Section: Direct‐acting Antiviral Treatment In Mixed Cryoglobulinemia mentioning

confidence: 99%

“…Studies demonstrate that DAA regimens achieve SVR in 95% (297 out of 313) of patients with HCV-MCS, which is similar to cure rates in the general population with HCV. [87][88][89][90][91][92][93][94][95][96][97][98] There are currently no reports of HCV-MCS treated with more recently approved DAAs, such as sofosbuvir/velpatasvir/voxilaprevir, elbasvir/grazoprevir, glecaprevir/pibrentasvir, or sofosbuvir/velpatasvir, but there is no reason to think that these agents would be less effective in HCV-MCS. The complete clinical remission rate of HCV-MCS symptoms after IFN-free DAA therapy ranged widely between studies but across all studies, 85% of patients were reported to have either a partial (20%) or complete clinical response (65%).…”

Section: Ifn-free Daa Regimensmentioning

confidence: 99%

“…The complete clinical remission rate of HCV-MCS symptoms after IFN-free DAA therapy ranged widely between studies but across all studies, 85% of patients were reported to have either a partial (20%) or complete clinical response (65%). [87][88][89][90][91][92][93]99 Achieving clinical remission was tied to SVR status, but there were several cases of complete clinical response in patients who relapsed virologically. 46,[85][86][87][88][89][90]95,98 Overall, 54% of DAA-treated patients with SVR had a complete clinical response (defined as improvement or resolution of all the baseline vasculitis symptoms and lack of clinical relapse).…”

Section: Ifn-free Daa Regimensmentioning

confidence: 99%

“…Overall, only 3/192 (1.6%) patients treated with IFN-free DAAs discontinued treatment early. [88][89][90]92,95,96 Figure 3 Hepatitis C virus and targets for direct-acting antiviral therapy. Figure 4 Schematic representation of virologic, clinical, and immunologic outcomes for patients with HCV-MCS who are treated with DAAs.…”

Section: Adverse Events During Daa Treatmentmentioning

confidence: 99%

See 4 more Smart Citations

Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis

Rutledge

Chung

Sise

2018

Hemodialysis International

View full text Add to dashboard Cite

Cryoglobulinemia is a common extrahepatic manifestation of infection with hepatitis C virus (HCV). When signs and symptoms of systemic vasculitis or glomerulonephritis occur in the presence of circulating cryoglobulins, this syndrome is called "mixed cryoglobulinemia syndrome" (MCS). Historically, interferon-based therapies in HCV have been associated with lower rates of viral cure in patients with MCS than in the general HCV-infected population. The advent of direct-acting antiviral therapies have revolutionized the treatment of HCV, dramatically increasing rates of cure. Early studies of first-generation protease inhibitors (telaprevir and boceprevir) in combination with interferon and ribavirin demonstrated HCV cure rates of 67% and complete clinical response rates of vasculitis symptoms in 60% of patients with MCS; however, regimens were poorly tolerated by patients, 22% discontinued treatment early. More recently, all-oral, interferon-free regimens have become available and combination therapies are now being approved for patients with and without renal impairment. Patients with HCV-MCS achieved sustained virologic response in 297 out of 313 patients (95%) treated with direct-acting antiviral therapy, and 85% had a complete or partial clinical response of MCS symptoms. Current direct-acting antiviral therapies are well tolerated in patients with HCV-MCS and only 1.6% discontinued treatment early. Patients with cryoglobulinemic glomerulonephritis also had an excellent cure rate (94%). The majority improved; 17/52 (33%) experienced full remission and 15/52 (29%) experienced partial remission. There were no reports of worsening kidney function in patients treated with direct-acting antiviral therapies. Less than 5% of patients with HCV-MCS treated with IFN-free direct-acting antiviral therapy required immunosuppression. However, patients with severe vasculitis appear to still require concomitant immunosuppression.

show abstract

Section: Direct‐acting Antiviral Treatment In Mixed Cryoglobulinemia mentioning

confidence: 95%

Section: Direct‐acting Antiviral Treatment In Mixed Cryoglobulinemia mentioning

confidence: 99%

Section: Ifn-free Daa Regimensmentioning

confidence: 99%

Section: Ifn-free Daa Regimensmentioning

confidence: 99%

Section: Adverse Events During Daa Treatmentmentioning

confidence: 99%

See 3 more Smart Citations

Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis

Rutledge

Chung

Sise

2018

Hemodialysis International

View full text Add to dashboard Cite

show abstract

Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: A systematic review

Akram

Tahir

Shah

et al. 2018

Phytotherapy Research

222

170

View full text Add to dashboard Cite

Viral infections are being managed therapeutically through available antiviral regimens with unsatisfactory clinical outcomes. The refractory viral infections resistant to available antiviral drugs are alarming threats and a serious health concern. For viral hepatitis, the interferon and vaccine therapies solely are not ultimate solutions due to recurrence of hepatitis C virus. Owing to the growing incidences of viral infections and especially of resistant viral strains, the available therapeutic modalities need to be improved, complemented with the discovery of novel antiviral agents to combat refractory viral infections. It is widely accepted that medicinal plant heritage is nature gifted, precious, and fueled with the valuable resources for treatment of metabolic and infectious disorders. The aims of this review are to assemble the facts and to conclude the therapeutic potential of medicinal plants in the eradication and management of various viral diseases such as influenza, human immunodeficiency virus (HIV), herpes simplex virus (HSV), hepatitis, and coxsackievirus infections, which have been proven in diverse clinical studies. The articles, published in the English language since 1982 to 2017, were included from Web of Science, Cochrane Library, AMED, CISCOM, EMBASE, MEDLINE, Scopus, and PubMed by using relevant keywords including plants possessing antiviral activity, the antiviral effects of plants, and plants used in viral disorders. The scientific literature mainly focusing on plant extracts and herbal products with therapeutic efficacies against experimental models of influenza, HIV, HSV, hepatitis, and coxsackievirus were included in the study. Pure compounds possessing antiviral activity were excluded, and plants possessing activity against viruses other than viruses in inclusion criteria were excluded. Hundreds of plant extracts with antiviral effect were recognized. However, the data from only 36 families investigated through in vitro and in vivo studies met the inclusion criteria of this review. The inferences from scientific literature review, focusing on potential therapeutic consequences of medicinal plants on experimental models of HIV, HSV, influenza, hepatitis, and coxsackievirus have ascertained the curative antiviral potential of plants. Fifty-four medicinal plants belonging to 36 different families having antiviral potential were documented. Out of 54 plants, 27 individually belong to particular plant families. On the basis of the work of several independent research groups, the therapeutic potential of medicinal plants against listed common viral diseases in the region has been proclaimed. In this context, the herbal formulations as alternative medicine may contribute to the eradication of complicated viral infection significantly. The current review consolidates the data of the various medicinal plants, those are Sambucus nigra, Caesalpinia pulcherrima, and Hypericum connatum, holding promising specific antiviral activities scientifically proven through studies on experimental animal mo...

show abstract

Natural Plants in the Treatment of Renal Syndrome Caused by Viruses: Ethnopharmacology, Chemistry, Clinical and Preclinical Studies

Mondal¹,

Banerjee²,

Chakraborty³

et al. 2023

Reference Series in Phytochemistry

View full text Add to dashboard Cite

Sofosbuvir/Ribavirin treatment in patients with genotype 2, Hepatitis C Virus infection and symptomatic mixed cryoglobulinemia: an interim analysis on safety, efficacy and impact on quality of life

Cited by 9 publications

References 0 publications

Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis

Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis

Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: A systematic review

Natural Plants in the Treatment of Renal Syndrome Caused by Viruses: Ethnopharmacology, Chemistry, Clinical and Preclinical Studies

Contact Info

Product

Resources

About